Hopes and Cures

Both Forbes and East Coast Blogging mentions that people can now apply for the $6 million in biotechnology tax credits in Maryland.  They didn’t discuss how enthusiastic the Maryland Biotech community is over this new plan.
 
There is a lot of growing excitement over Governor O’Malley’s BIO 2020 Initiative.  Today, the Baltimore Sun covered what [...]

Filed under: BIO | Tagged: biotech, Gov. OMalley, MD | No Comments »

Recently, there was an interesting study conducted by PricewaterhouseCoopers, the New England Healthcare Institute, the Massachusetts Life Sciences Center, Xconomy and the Massachusetts Technology Collaborative on the Massachusetts Life Sciences Super Cluster, showing the value of a strong science sector economically.   This Super Cluster includes Universities, teaching hospitals, biotechnology, medical device, and pharmaceutical companies.  Software, [...]

Filed under: BIO, In the News, SBIR, venture capital | Tagged: biotech, MA, Pricewaterhouse, Study, VC | No Comments »

Yesterday, the House voted overwhelmingly (368-43), to reauthorize the Small Business Innovation Research (SBIR) program.  This bill will allow more biotechnology companies to compete for research funding.
This act will increase access to early-stage funding for treatments and cures for debilitating diseases.  Congress has recognized the capital-intensive needs of emerging biotechnology companies, whose development of a [...]

Filed under: BIO, Congress, SBIR, patient groups, venture capital | Tagged: Committee, House, SBIR, Science, treatments | No Comments »

California Biotech Law Blog posted a summary of recent House hearings on reauthorizing the Small Business Innovation Research Program (SBIR).

In the world of biotechnology, the principle at stake is the United States’s claim to be an innovation engine in the global economy. Our members and their scientists are developing disease treatments and cures at a rapid rate, but because these cutting-edge treatments are so new, it takes 10-15 years before they reach the market. In the meantime, they thrive on traditional venture capital and the government’s version of VC: the SBIR program.

If Congress wants to perpetuate the image – and reality – of the US as the center of innovation, they must adapt the criteria for SBIR grants to match the reality for these budding treatments and burgeoning companies.

Filed under: BIO, Congress, Finding Cures, SBIR, venture capital | Tagged: SBIR, biotech, MS, Parkinson's | No Comments »

Here at BIO, we are rethinking our online strategy and we can’t do it without you. Help us provide you with the best online information, tools and resources possible and…..
Take our survey!

Filed under: BIO | Tagged: BIO | No Comments »